Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Meeting ReportMolecular Targeting Probes-Radioactive & Nonradioactive - Preclinical Probes for Oncology

In vivo PET imaging of 5T4 positive tumor cells using 89Zr-DFO-MY9

Dan Li, Qi Wang, Min Zhu, Yakun Wan, Zhi Yang and Hua Zhu
Journal of Nuclear Medicine June 2024, 65 (supplement 2) 242487;
Dan Li
1Peking University Cancer Hospital
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Qi Wang
1Peking University Cancer Hospital
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Min Zhu
2Shanghai Novamab Biopharmaceuticals Co., Ltd.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yakun Wan
2Shanghai Novamab Biopharmaceuticals Co., Ltd.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Zhi Yang
3Beijing Cancer Hospital& Institute
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Hua Zhu
4Peking University Cancer Hospital & Institute
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
Loading

Abstract

242487

Introduction: Background: The 5T4 oncofoetal antigen is considered a valuable tumor-associated antigen, which is expressed in many different cancers, but is rarely expressed in normal adult tissues. And cell surface expression of 5T4 is an important property for antibody-targeted therapies. It has been shown that 5T4 is expressed on tumour-initiating cells (TICs) and associated with worse clinical outcome. Moreover, decreased adherence due to 5T4 expression may be associated with cancer spread.

Purpose: Herein, we generate and labeled the 5T4 targeting antibody fragments (MY9) with 89Zr, and investigate whether positron-emission tomography (PET) were sensitive approaches for detecting and quantitating 5T4+ solid tumor in vivo.

Methods: MY9was labeled with 89Zr (using DFO as bi-functional chelator). The quality control was analyzed by Radio-TLC. The invitro stability was evaluated in saline and 5%HSA. Micro-PET imaging studies were performed in BxPC3 and MDA-MB-231 tumor models. Both model mice were injected with 3.33 MBq of 89Zr-DFO-MY9 via tail vein. Then 10 min static PET scans were acquired at each time point from 3 h to 144 h post injection (p.i.), respectively. Using a small-animal PET/CT scanner, the PET images were reconstructed by Avatar 3.

Results: 89Zr-DFO-MY9 were successfully constructed with 80-90% yield over 99% radiochemical purity. The radiochemical purity of 89Zr-DFO-MY9 at 120 h after labeling showed high in vitro stability. The tumor uptake of 89Zr-DFO-MY9 in BxPC3 models could be clearly visualized at 15 h with SUVmax 2.69 ± 0.31 and remained to be clearly visible up to 144 h post-injection. The tumor uptake of 89Zr-DFO-MY9 in MDA-MB-231 models could be clearly visualized at 24 h with SUVmax 1.65 ± 0.24 and remained to be clearly visible up to 96 h post-injection.

Conclusions: 5T4 is an attractive target for immune intervention in cancer. Targeted molecular imaging allows for real-time, noninvasive, and quantitative detection of 5T4+ TICs in vivo. It may be possible to early warning of early detection of tumor prognosis and recurrence.

Figure
  • Download figure
  • Open in new tab
  • Download powerpoint
Previous
Back to top

In this issue

Journal of Nuclear Medicine
Vol. 65, Issue supplement 2
June 1, 2024
  • Table of Contents
  • Index by author
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
In vivo PET imaging of 5T4 positive tumor cells using 89Zr-DFO-MY9
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
In vivo PET imaging of 5T4 positive tumor cells using 89Zr-DFO-MY9
Dan Li, Qi Wang, Min Zhu, Yakun Wan, Zhi Yang, Hua Zhu
Journal of Nuclear Medicine Jun 2024, 65 (supplement 2) 242487;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
In vivo PET imaging of 5T4 positive tumor cells using 89Zr-DFO-MY9
Dan Li, Qi Wang, Min Zhu, Yakun Wan, Zhi Yang, Hua Zhu
Journal of Nuclear Medicine Jun 2024, 65 (supplement 2) 242487;
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Figures & Data
  • Info & Metrics

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • PD-L1 imaging and T cell imaging jointly achieve precise combination therapy of radiotherapy and immunotherapy
  • Optimizing Fc-engineered novel anti-MSLN VH-Fc fusion proteins through PET imaging
  • PET Imaging of Tumor PD-L1 Expression with a 18F-labeled Bicyclic Peptide
Show more Molecular Targeting Probes-Radioactive & Nonradioactive - Preclinical Probes for Oncology

Similar Articles

SNMMI

© 2025 SNMMI

Powered by HighWire